Fifty Presentations and Posters Will Describe Results Generated
with Single Molecule Real-Time Technology at This Week’s
Single Molecule Real Time (SMRT®) sequencing products, today
announced it has released a major upgrade to its PacBio® RS
system, referred to as “C2”, including new chemistry, enhanced SMRT
Cells and upgraded software, which together provide customers with
significant performance increases for DNA sequencing. The company and
numerous customers will discuss their progress with the platform through
a total of 50 presentations and posters at the 2012 Advances in Genome
Biology & Technology (AGBT) meeting this week in
The PacBio RS is a revolutionary DNA sequencing system that
reveals new biological insights by incorporating novel, single molecule
sequencing techniques, advanced analytics, and long read lengths.
Compared with the C1 versions launched with the system in
the PacBio C2 chemistry and software provide approximately:
-
2x increase in average read length;
-
3-4x improvement in mappable data per SMRT Cell;
-
50-80% reduction in input DNA required; and
-
Consensus accuracy of Q50 (99.999%) at substantially lower coverage.
“The changes we’ve made with this upgrade enable significant performance
increases and lay the foundation for ongoing enhancements to the PacBio RS,”
said
“We’re very proud of how far we’ve come in the nine months since we
first released the product commercially, and even more proud of our
customers’ achievements, many of which will be highlighted this week at
AGBT.”
Sciences (IGS) at the University of
among the institutions that had early access to a preliminary version of
the new chemistry.
“The Sanger Institute has seen significant improvements in performance
compared to C1, enhancing our research projects in the areas of de
novo genome assembly, sequencing through repetitive elements,
enabling coverage of regions with extreme base composition, and
improving genome assemblies,” said
Research and Development at the
added: “Early access to the new chemistry has resulted in significantly
improved read lengths compared to the original C1 chemistry. These
longer reads have enhanced our de novo genome assembly of
microbial genomes when combined with short-read data. The longer read
lengths have also increased our ability to generate higher-accuracy
circular consensus reads.”
The latest generation of SMRT Cells is more robust due to an improved
manufacturing process, and the PacBio RS software has been
enhanced for improved reliability and greater performance. To date,
Pacific Biosciences has developed two whole product solutions that
leverage the capabilities of the PacBio RS system to uniquely
enable key customer applications: 1) de novo whole genome
assembly and 2) targeted sequencing. As an example, the SMRT Analysis
software incorporates The
Genome Analysis Toolkit (GATK) developed by the
This provides a streamlined pipeline for variant analysis for targeted
sequencing.
This week’s AGBT conference will feature a total of 35 presentations and
posters from PacBio customers, largely highlighting the two key
applications for the system. Scientists from PacBio will also present a
total of 15 presentations and posters about the technology. Details are
available at www.pacb.com/agbt2012.
For more information about Pacific Biosciences, please visit www.pacb.com.
You can also follow the company on Twitter www.twitter.com/pacbio.
About
Pacific Biosciences’ mission is to transform the way humankind acquires,
processes and interprets data from living systems through the design,
development and commercialization of innovative tools for biological
research. The company has developed a novel approach to studying the
synthesis and regulation of DNA, RNA and proteins. Combining recent
advances in nanofabrication, biochemistry, molecular biology, surface
chemistry and optics, Pacific Biosciences has created a powerful
technology platform called single molecule, real-time, or SMRT®,
technology. SMRT technology enables real-time analysis of biomolecules
with single molecule resolution, which has the potential to transform
the understanding of biological systems by providing a window into these
systems that has not previously been open for scientific study.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements may contain words such as “believe,” “may,” “estimate,”
“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of
these terms, or other similar expressions, and include the assumptions
that underlie such statements. Such statements include, but are not
limited to, statements regarding the Company’s SMRT technology. These
statements are subject to known and unknown risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements, including but not limited to risks discussed
from time to time in documents
has filed with the
risks identified under the section captioned “Risk Factors” in its
recently filed Quarterly Report on Form 10-Q. All forward-looking
statements are based on estimates, projections and assumptions as of the
date hereof. Pacific Biosciences undertakes no obligation to update any
forward-looking statements.
Media:
For Pacific Biosciences
Litchfield, 415-793-6468
nicole@bioscribe.com
or
Investors:
Pacific
Biosciences
ir@pacificbiosciences.com
Source:
News Provided by Acquire Media